Paper Details

  1. Home
  2. Paper Details

A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer.

Author: CashmanJohn R, ChengJiongjia, Gomez-GalenoJorge, LeeDong-Hoon, MooreStephanie, OkolotowiczKarl J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

PAWI-2 is a novel molecule that effectively inhibits the growth of prostate cancer cells, both androgen-sensitive and androgen-insensitive, in vitro and in vivo. It works independently of androgen receptor signaling and shows promise in overcoming enzalutamide resistance in castration-resistant prostate cancer. Furthermore, PAWI-2 synergizes with enzalutamide, a clinically used drug, to inhibit tumor growth.
Paper Details　
Original Abstract of the Article :
Prostate cancer (PCa) is the second leading cause of cancer-related death for men in the United States. Approximately 35% of PCa recurs and is often transformed to castration-resistant prostate cancer (CRPCa), the most deadly and aggressive form of PCa. However, the CRPCa standard-of-care treatment ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042720/

データ提供：米国国立医学図書館（NLM）

PAWI-2: A Novel Small Molecule for Treating Prostate Cancer

The [treatment of prostate cancer] is an ongoing area of research, with a particular focus on overcoming the challenges of castration-resistant prostate cancer (CRPCa). This study introduces PAWI-2, a novel small molecule, as a potential new weapon in the fight against prostate cancer.

The researchers found that PAWI-2 effectively inhibited cell proliferation in both androgen-sensitive and androgen-insensitive prostate cancer cell lines. In vivo studies in a PC-3 xenograft model showed that PAWI-2 significantly inhibited tumor growth. Furthermore, PAWI-2 demonstrated synergy with enzalutamide, a currently used drug for CRPCa, in inhibiting prostate cancer cell viability and tumor growth.

PAWI-2: A Promising New Approach for Prostate Cancer Treatment

The study findings suggest that PAWI-2, much like a refreshing oasis in a parched desert, could be a valuable addition to the treatment options for prostate cancer. Its ability to inhibit tumor growth regardless of androgen receptor status and its synergistic effects with enzalutamide hold promise for improving treatment outcomes for patients with CRPCa.

Prostate Cancer: Understanding the Complexities of Treatment

Navigating the complexities of prostate cancer can be a challenging journey, much like a camel traversing a vast and unpredictable desert. This study offers a ray of hope by introducing PAWI-2, a novel small molecule that holds potential for improving treatment outcomes. It underscores the importance of ongoing research to develop new and effective therapies for this disease.

Dr.Camel's Conclusion

This study ventures into the challenging landscape of prostate cancer, seeking new paths to overcome the obstacles of CRPCa. PAWI-2, like a desert traveler finding a hidden spring, offers a promising new avenue for treatment. Remember, the journey to find effective therapies is ongoing, and we must continue to support research efforts to improve patient care and combat this disease.

Date :
  1. Date Completed 2020-04-27
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31582422

DOI: Digital Object Identifier

PMC7042720

Related Literature

Article Analysis
・Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.